Lixte Biotechnology Holdings Dividend

Dividend criteria checks 0/6

Lixte Biotechnology Holdings does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield	2.9%
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Earnings per share	-US$2.26
Dividend yield forecast in 3Y	n/a

Recent dividend updates

No updates

Recent updates

We Think Lixte Biotechnology Holdings (NASDAQ:LIXT) Can Afford To Drive Business Growth

Jul 20

Lixte Biotechnology starts enrollment in early-stage lung cancer study

Jun 02

Will Lixte Biotechnology Holdings (NASDAQ:LIXT) Spend Its Cash Wisely?

Feb 25

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if LIXT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LIXT's dividend payments have been increasing.

Dividend Yield vs Market

Lixte Biotechnology Holdings Dividend Yield vs Market

How does LIXT dividend yield compare to the market?
Segment	Dividend Yield
Company (LIXT)	n/a
Market Bottom 25% (US)	1.6%
Market Top 25% (US)	4.8%
Industry Average (Biotechs)	2.9%
Analyst forecast in 3 Years (LIXT)	n/a

Notable Dividend: Unable to evaluate LIXT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate LIXT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate LIXT's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as LIXT has not reported any payouts.

Lixte Biotechnology Holdings Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Recent updates

New major risk - Share price stability

Lixte Biotechnology Holdings, Inc. Announces Publication of Pre-Clinical Data in the Online Journal

LIXTE Biotechnology Holdings, Inc. Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments

Lixte Biotechnology Holdings, Inc., Annual General Meeting, Nov 27, 2023

Lixte Biotechnology Holdings, Inc. Announces Chief Executive Officer Changes

LIXTE Biotechnology Holdings, Inc. Announces Supported Collaborative Trial to Study LIXTE’s First-in-Class PP2A Inhibitor, LB-100, Plus GSK’s Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer

New minor risk - Shareholder dilution

New major risk - Share price stability

LIXTE Biotechnology Holdings, Inc. Announces the Enrollment of the First Patient in the Phase 1b Portion of the Phase 1b/2 Protocol

LIXTE Biotechnology Announces 1-for-10 Reverse Stock Split to Bring it into Compliance with Nasdaq’s Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market

Lixte Biotechnology Holdings, Inc. Announces Recently Published Independent Research Reveals New Mechanisms

Will Lixte Biotechnology Holdings (NASDAQ:LIXT) Spend Its Cash Wisely?

Lixte Biotechnology Holdings, Inc. Promotes Eric Forman to Vice President and Chief Operating Officer

LIXTE Biotechnology Holdings, Inc. Announces Spanish Agency for Medicines and Health Products Authorized Phase 1b/Randomized Phase 2 Study of LB-100

Lixte Biotechnology Holdings, Inc., Annual General Meeting, Oct 07, 2022

Lixte Biotechnology Holdings, Inc. Appoints Bastiaan Van Der Baan as Independent Director

Lixte Biotechnology Holdings, Inc. Appoints Bas Van Der Baan to Its Board of Directors

Lixte Biotechnology Holdings, Inc. Announces Appointment of Professor René Bernards to its Board of Directors

Philip Palmedo Not to Stand for Re-Election as Director of Lixte Biotechnology Holdings, Inc

Will Lixte Biotechnology Holdings (NASDAQ:LIXT) Spend Its Cash Wisely?

Will Lixte Biotechnology Holdings (NASDAQ:LIXT) Spend Its Cash Wisely?

Lixte Biotechnology’s LB-100 Reported to Convert Immunologically Unresponsive (“Cold”) Tumors to Immunologically Responsive (“Hot”) Tumors

Lixte Biotechnology Holdings, Inc. Announces Enrollment Has Resumed in National Cancer Institute’s Trial to Determine Ability of Lixte Compound LB-100 to Enter Recurrent, Malignant Brain Tumors

LixteBiotechnology Holdings, Inc.'s Pre-Clinical Research Demonstrates Inhibition of Protein Phosphatase 2A with LB-100 Combined with the Experimental Drug, Vosoritide

We Think Lixte Biotechnology Holdings (NASDAQ:LIXT) Can Afford To Drive Business Growth

Lixte Biotechnology Holdings, Inc.(NasdaqCM:LIXT) dropped from Russell 3000E Value Index

Lixte Biotechnology and City of Hope Enroll First Patient in Phase 1b Trial of Lead Compound LB-100 for Treatment of Small Cell Lung Cancer

Lixte Biotechnology starts enrollment in early-stage lung cancer study

Independent Director has left the company

Lixte Biotechnology Holdings, Inc. to Showcase Its Anti-Cancer Therapy Enhancer LB-100 At the Virtual Annual Roth Capital Conference

New 90-day high: US$5.58

Will Lixte Biotechnology Holdings (NASDAQ:LIXT) Spend Its Cash Wisely?

New 90-day low: US$3.05

Lixte Biotechnology Holdings, Inc. and City of Hope to Initiate Phase 1b Clinical Trial of Lixte’S Lead Compound Lb-100 to Treat Small Cell Lung Cancer

New 90-day low: US$3.14

New 90-day low: US$3.59

New 90-day low: US$3.60

New 90-day low: US$3.65

Lixte Biotechnology Holdings Deleted from Other OTC

New 90-day low: US$3.74

Lixte Biotechnology Holdings, Inc. has completed an IPO in the amount of $5.7 million.

Lixte Biotechnology Holdings, Inc. has filed an IPO in the amount of $10.668 million.

Stability and Growth of Payments

Dividend Yield vs Market

Earnings Payout to Shareholders

Cash Payout to Shareholders

Discover strong dividend paying companies